Mevastatin

Key Product Details

Product Description

Mevastatin is an inhibitor of HMG-CoA reductase; decreases cholesterol biosynthesis, in vitro and in vivo. Induces apoptosis, arrests cancer cells in G1 phase and downregulates cdk 2, 4, and 6, cyclin D1 and E1, p21 and p27. Inactive lactam prodrug of mevastatin hydroxy acid, naturally bioactivated in vivo following oral administration.

Product Specifications for Mevastatin

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.

Solubility

Preparing Stock Solutions for Mevastatin

The following data is based on the product molecular weight 390.52.

Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which all affect the solvent volumes required to prepare stock solutions.

Select a batch to recalculate based on the batch molecular weight:

1 Recalculate

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
0.5 mM	5.12 mL	25.61 mL	51.21 mL
2.5 mM	1.02 mL	5.12 mL	10.24 mL
5 mM	0.51 mL	2.56 mL	5.12 mL
25 mM	0.10 mL	0.51 mL	1.02 mL

Calculators

Background References

References are publications that support the biological activity of the product. See our Citations tab to view 10 publications citing the usage of this product.

• Cohen Effects of compactin, mevalonate and low-density lipoprotein on 3-hydroxy-3-methylglutaryl-coenzyme A reductase activity and low-density lipoprotein-receptor activity in the human hepatoma cell line Hep G2. Biochem.J. 1984 PMID: 6089762
• Wachtershauser HMG-CoA reductase inhibitor mevastatin enhances the growth inhibitory effect of butyrate in the colorectal carcinoma cell line Caco-2. Carcinogenesis 2001 PMID: 11408350
• Amin-Hanjani Mevastatin, an HMG-CoA reductase inhibitor, reduces stroke damage and upregulates endothelial nitric oxide synthase in mice. Stroke 2001 PMID: 11283400

Product Documents for Mevastatin